Arrowstreet Capital Limited Partnership lifted its position in shares of CME Group Inc (NASDAQ:CME) by 53.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,201,333 shares of the financial services provider’s stock after purchasing an additional 764,129 shares during the quarter. CME Group comprises 0.8% of Arrowstreet Capital Limited Partnership’s investment portfolio, making the stock its 28th biggest holding. Arrowstreet Capital Limited Partnership’s holdings in CME Group were worth $321,505,000 at the end of the most recent reporting period.
Other institutional investors also recently added to or reduced their stakes in the company. Valeo Financial Advisors LLC bought a new stake in CME Group in the third quarter worth $124,000. Bank of Nova Scotia Trust Co. bought a new stake in CME Group in the third quarter worth $165,000. SeaCrest Wealth Management LLC bought a new stake in CME Group in the fourth quarter worth $203,000. Wesbanco Bank Inc. bought a new stake in CME Group in the fourth quarter worth $205,000. Finally, Dempze Nancy E bought a new stake in CME Group in the fourth quarter worth $205,000. 82.85% of the stock is currently owned by institutional investors and hedge funds.
Shares of CME Group Inc (NASDAQ:CME) opened at $162.38 on Monday. The company has a market capitalization of $55,260.00, a price-to-earnings ratio of 37.07, a P/E/G ratio of 2.10 and a beta of 0.64. The company has a current ratio of 1.03, a quick ratio of 1.05 and a debt-to-equity ratio of 0.10. CME Group Inc has a 1 year low of $114.82 and a 1 year high of $165.35.
CME Group (NASDAQ:CME) last posted its quarterly earnings data on Thursday, February 1st. The financial services provider reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.02. The company had revenue of $900.00 million during the quarter, compared to analysts’ expectations of $886.85 million. CME Group had a return on equity of 7.68% and a net margin of 111.49%. CME Group’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.14 earnings per share. equities analysts forecast that CME Group Inc will post 6.32 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 26th. Investors of record on Friday, March 9th will be given a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a yield of 1.72%. The ex-dividend date of this dividend is Thursday, March 8th. This is a boost from CME Group’s previous quarterly dividend of $0.66. CME Group’s dividend payout ratio is 60.27%.
A number of research analysts have recently issued reports on the company. Barclays upped their price target on CME Group from $170.00 to $175.00 and gave the company an “overweight” rating in a report on Friday, February 2nd. Sandler O’Neill reaffirmed a “buy” rating and set a $175.00 price target on shares of CME Group in a report on Friday, February 2nd. Citigroup reaffirmed a “buy” rating and set a $172.00 price target (up from $155.00) on shares of CME Group in a report on Monday, January 29th. BidaskClub downgraded CME Group from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Finally, Bank of America upped their price target on CME Group from $173.00 to $175.00 and gave the company a “buy” rating in a report on Friday, February 2nd. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $157.00.
In other CME Group news, Chairman Terrence A. Duffy sold 20,000 shares of the company’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $151.66, for a total value of $3,033,200.00. Following the completion of the sale, the chairman now owns 99,239 shares in the company, valued at $15,050,586.74. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Derek Sammann sold 2,400 shares of the company’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $161.66, for a total value of $387,984.00. Following the completion of the sale, the insider now owns 40,153 shares of the company’s stock, valued at approximately $6,491,133.98. The disclosure for this sale can be found here. In the last quarter, insiders have sold 64,728 shares of company stock valued at $9,755,257. 0.57% of the stock is owned by company insiders.
WARNING: “Arrowstreet Capital Limited Partnership Grows Position in CME Group Inc (CME)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/19/arrowstreet-capital-limited-partnership-grows-position-in-cme-group-inc-cme.html.
CME Group Profile
CME Group Inc, through its exchanges, provides products across all asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural products and metals. The Company’s segment primarily consists of the Chicago Mercantile Exchange Inc (CME), Board of Trade of the City of Chicago, Inc (CBOT), New York Mercantile Exchange, Inc (NYMEX) and Commodity Exchange, Inc (COMEX) exchanges.
Want to see what other hedge funds are holding CME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CME Group Inc (NASDAQ:CME).
Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.